Nektar Therapeutics announced on February 10, 2026, that its experimental drug rezpegaldesleukin (rezpeg) maintained skin responses in 71% (monthly) and 83% (quarterly) of moderate-to-severe eczema patients after one year in the Phase 2b REZOLVE-AD trial124
Responses deepened over time, with 2-5 fold increase in patients achieving total lesion clearance (EASI-100), and rates numerically higher than Dupixent for EASI-7534
Nektar plans Phase 3 trial starting Q2 2026, aiming for FDA approval in 2029; stock rose 51% on announcement34
No search results confirm recent news of Pfizer ending a malnutrition trial as of February 11, 2026.
Sources:
1. https://www.statnews.com/2026/02/10/nektar-therapeutics-rezpeg-eczema-drug-maintains-skin-response-study/
2. https://www.biopharmadive.com/news/nektar-rezpegaldesleukin-eczema-maintenance-data-results/811806/
3. https://www.biospace.com/drug-development/nektars-rezpeg-differentiates-in-atopic-dermatitis-with-durable-deep-responses-in-mid-stage
4. https://www.clinicaltrialsarena.com/news/nektar-therapeutics-rezpeg-atopic-dermatitis-phase-ii-rezolve-ad-study/